Lexaria Equity Financing and Corporate Strategy Update

Kelowna, British Columbia – TheNewswire – October 30, 2019 – Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it is arranging a non-brokered private placement for gross proceeds of approximately US$1 million (the “Financing”). The Financing is comprised of units (“Units”) being issued at a price of US$0.45 per Unit. Each Unit shall consist of one common share of the Company (a “Share”) and one Share purchase warrant (each Share purchase warrant, a “Warrant”). Each Warrant shall entitle the holder to acquire one additional Share (the “Warrant Share”) for a period of two years from the date of issue (the “Expiry Date”). The Warrants shall be exercisable at a price of US$0.80 per Warrant Share during the first 12 months of issuance and thereafter at a price of US$1.20 per Warrant Share until the Expiry Date. The net proceeds of the Financing will be used to accelerate DehydraTECHTM-based technology and formulation development; for increased intellectual property and patent pursuit; and for general corporate purposes. Earlier this year, Lexaria moved into its new head office with a Health Canada licensed research and development laboratory that is now conducting world-leading research into drug…

Excerpt only …
READ MORE BELOW
Source : New feed
Link to original : Lexaria Equity Financing and Corporate Strategy Update
reposted by Cannabis News World